Denosis (SC Injection 60 mg/ml 1 ml pre-filled syringe)

Denosis is a RANK ligand (RANKL) inhibitor indicated for: Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Denosis is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Denosis reduces the incidence of vertebral, nonvertebral, and hip fractures. Treatment to Increase Bone Mass in Men with Osteoporosis: Denosis is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Treatment of Glucocorticoid-Induced Osteoporosis: Denosis is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Denosis is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Denosis also reduced the incidence of vertebral fractures. Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer: Denosis is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Treatment of Multiple Myeloma and Bone Metastasis from Solid Tumors: Denosis is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of Giant Cell Tumor of Bone: Denosis is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of Hypercalcemia of Malignancy: Denosis is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

Add to cart